Tempest Therapeutics, Inc. (TPST) stock
TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.01 (-3.53%)
Close on Nov 12, 2026Market cap $5.67MP/E –Yield –
Tempest Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Tempest Therapeutics's ebitda for the twelve months ending Sep 30, 2018 was -$58.62M. For fiscal 2017 it was -$82.68M. The highest annual figure on record is -$13.44M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | -$82.68M | – |
| FY2016 | Dec 31, 2016 | -$78.77M | – |
| FY2015 | Dec 31, 2015 | -$70.71M | – |
| FY2014 | Dec 31, 2014 | -$47.48M | – |
| FY2013 | Dec 31, 2013 | -$28.90M | – |
| FY2012 | Dec 31, 2012 | -$13.44M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2018 | Sep 30, 2018 | -$7.71M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.79M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.06M | – |
| Q4 FY2017 | Dec 31, 2017 | -$42.07M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.01M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.43M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.13M | – |
| Q4 FY2016 | Dec 31, 2016 | -$21.78M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.36M | – |
See a number that looks wrong?